CompanyONCYNasdaqSan Diego, CA

Oncolytics Biotech

Oncolytics Biotech develops pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic in clinical trials for pancreatic, breast, colorectal, and anal cancers, primarily in combination with chemotherapy or checkpoint inhibitors.

Stories only

SEC EDGAR ClinicalTrials.gov oncolyticsbiotech.com

8-KSep 29Latest SEC filing

Sep 30Latest story

September 2026

Oncolytics reports faster enrollment in REO 033 colorectal cancer study

Sep 30Regulatory decisionOncolytics Biotech Sagimet Biosciences Inc.Updated

August 2026

Oncolytics gets FDA feedback on pivotal path for pelareorep in colorectal cancer

Aug 18Regulatory decisionOncolytics Biotech pelareorep

July 2026

Oncolytics wins FDA Fast Track for pelareorep in second-line anal cancer

Jul 20Regulatory milestoneOncolytics Biotech pelareorep